Stable Cell Line Development
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring stable cell line development services to generate larger quantities of purified monoclonal antibodies (mAb-G and mAb-NG) for method validation work. The requirement calls for development of three stable cell lines expressing recombinant mAb-G (full-length form only) and mAb-NG (both full-length and single-chain forms), driven by the low production yield from existing mouse hybridomas. The solicitation is estimated to release on November 1, 2026, with award targeted for January 1, 2027.
The estimated award value ranges from $25,000 to $250,000. Inquiries should be directed to the FDA's Acquisition Liaison at cderacquisitions@fda.hhs.gov.
Forecast text
The ongoing work is to validate the method, which will require larger quantities of purified mAb-G and mAb-NG. Due to the low production yield of mAb-G and mAb-NG from available mouse hybridomas, 3 stable cell lines expressing recombinant mAb-G and mAb-NG - full-length form for mAb-G only, and both full-length and single-chain forms for mAb-NG- are needed.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast